Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada

Nisha Andany, Janet M. Raboud, Sharon Walmsley, Christina Diong, Sean B. Rourke, Sergio Rueda, Anita Rachlis, Wendy Wobeser, Rodger David MacArthur, Louise Binder, Ron Rosenes, Mona R. Loutfy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: This study assessed ethnicity and gender differences in prevalence, type, and severity of antiretroviral-associated lipodystrophy in HIV-positive individuals in Ontario. Methods: This was a cross-sectional analysis of the Ontario Cohort Study (OCS), a prospective study of HIV-positive patients in Ontario. Lipodystrophy was defined as at least 1 major or 2 minor self-reported changes of peripheral lipoatrophy and/or central lipohypertrophy. Prevalence, type, and severity were compared by ethnicity (Black, White, or Other) and gender. Univariate and multivariate logistic regression analyses identified predictors of lipodystrophy. Results: Data were available for 778 participants (659 men, 119 women). There were 517 Whites, 121 Blacks, and 140 patients of Other ethnicities. In univariate analyses, Whites reported more peripheral lipoatrophy (P = .004) and abdominal lipohypertrophy (P = .04); these ethnic differences were observed in males (P = .05 and P = .03, respectively) but not females. Males reported more peripheral lipoatrophy (P = .01), whereas females had more central lipohypertrophy (P < .0001) and mixed fat redistribution (P < .0001). Multivariable regression analyses revealed Black women to be most vulnerable to lipodystrophy (P = .02), particularly lipohypertrophy (P < .0001). Conclusions: Ethnicity and gender are important factors influencing lipodystrophy. Combining lipoatrophy and lipohypertrophy into a single entity is not appropriate. Black women were most vulnerable to lipohypertrophy, which has important implications for antiretroviral therapy roll-out in Africa.

Original languageEnglish (US)
Pages (from-to)89-103
Number of pages15
JournalHIV Clinical Trials
Volume12
Issue number2
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Lipodystrophy
Ontario
Canada
HIV
HIV-Associated Lipodystrophy Syndrome
Regression Analysis
Therapeutics
Cohort Studies
Cross-Sectional Studies
Logistic Models
Fats
Prospective Studies
hydroquinone

Keywords

  • HIV
  • antiretroviral
  • ethnicity
  • gender
  • lipodystrophy

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Andany, N., Raboud, J. M., Walmsley, S., Diong, C., Rourke, S. B., Rueda, S., ... Loutfy, M. R. (2011). Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clinical Trials, 12(2), 89-103. https://doi.org/10.1310/hct1202-89

Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. / Andany, Nisha; Raboud, Janet M.; Walmsley, Sharon; Diong, Christina; Rourke, Sean B.; Rueda, Sergio; Rachlis, Anita; Wobeser, Wendy; MacArthur, Rodger David; Binder, Louise; Rosenes, Ron; Loutfy, Mona R.

In: HIV Clinical Trials, Vol. 12, No. 2, 01.01.2011, p. 89-103.

Research output: Contribution to journalArticle

Andany, N, Raboud, JM, Walmsley, S, Diong, C, Rourke, SB, Rueda, S, Rachlis, A, Wobeser, W, MacArthur, RD, Binder, L, Rosenes, R & Loutfy, MR 2011, 'Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada', HIV Clinical Trials, vol. 12, no. 2, pp. 89-103. https://doi.org/10.1310/hct1202-89
Andany, Nisha ; Raboud, Janet M. ; Walmsley, Sharon ; Diong, Christina ; Rourke, Sean B. ; Rueda, Sergio ; Rachlis, Anita ; Wobeser, Wendy ; MacArthur, Rodger David ; Binder, Louise ; Rosenes, Ron ; Loutfy, Mona R. / Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. In: HIV Clinical Trials. 2011 ; Vol. 12, No. 2. pp. 89-103.
@article{60464ff04bad461b9bc4903c6b5a8e30,
title = "Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada",
abstract = "Purpose: This study assessed ethnicity and gender differences in prevalence, type, and severity of antiretroviral-associated lipodystrophy in HIV-positive individuals in Ontario. Methods: This was a cross-sectional analysis of the Ontario Cohort Study (OCS), a prospective study of HIV-positive patients in Ontario. Lipodystrophy was defined as at least 1 major or 2 minor self-reported changes of peripheral lipoatrophy and/or central lipohypertrophy. Prevalence, type, and severity were compared by ethnicity (Black, White, or Other) and gender. Univariate and multivariate logistic regression analyses identified predictors of lipodystrophy. Results: Data were available for 778 participants (659 men, 119 women). There were 517 Whites, 121 Blacks, and 140 patients of Other ethnicities. In univariate analyses, Whites reported more peripheral lipoatrophy (P = .004) and abdominal lipohypertrophy (P = .04); these ethnic differences were observed in males (P = .05 and P = .03, respectively) but not females. Males reported more peripheral lipoatrophy (P = .01), whereas females had more central lipohypertrophy (P < .0001) and mixed fat redistribution (P < .0001). Multivariable regression analyses revealed Black women to be most vulnerable to lipodystrophy (P = .02), particularly lipohypertrophy (P < .0001). Conclusions: Ethnicity and gender are important factors influencing lipodystrophy. Combining lipoatrophy and lipohypertrophy into a single entity is not appropriate. Black women were most vulnerable to lipohypertrophy, which has important implications for antiretroviral therapy roll-out in Africa.",
keywords = "HIV, antiretroviral, ethnicity, gender, lipodystrophy",
author = "Nisha Andany and Raboud, {Janet M.} and Sharon Walmsley and Christina Diong and Rourke, {Sean B.} and Sergio Rueda and Anita Rachlis and Wendy Wobeser and MacArthur, {Rodger David} and Louise Binder and Ron Rosenes and Loutfy, {Mona R.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1310/hct1202-89",
language = "English (US)",
volume = "12",
pages = "89--103",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada

AU - Andany, Nisha

AU - Raboud, Janet M.

AU - Walmsley, Sharon

AU - Diong, Christina

AU - Rourke, Sean B.

AU - Rueda, Sergio

AU - Rachlis, Anita

AU - Wobeser, Wendy

AU - MacArthur, Rodger David

AU - Binder, Louise

AU - Rosenes, Ron

AU - Loutfy, Mona R.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Purpose: This study assessed ethnicity and gender differences in prevalence, type, and severity of antiretroviral-associated lipodystrophy in HIV-positive individuals in Ontario. Methods: This was a cross-sectional analysis of the Ontario Cohort Study (OCS), a prospective study of HIV-positive patients in Ontario. Lipodystrophy was defined as at least 1 major or 2 minor self-reported changes of peripheral lipoatrophy and/or central lipohypertrophy. Prevalence, type, and severity were compared by ethnicity (Black, White, or Other) and gender. Univariate and multivariate logistic regression analyses identified predictors of lipodystrophy. Results: Data were available for 778 participants (659 men, 119 women). There were 517 Whites, 121 Blacks, and 140 patients of Other ethnicities. In univariate analyses, Whites reported more peripheral lipoatrophy (P = .004) and abdominal lipohypertrophy (P = .04); these ethnic differences were observed in males (P = .05 and P = .03, respectively) but not females. Males reported more peripheral lipoatrophy (P = .01), whereas females had more central lipohypertrophy (P < .0001) and mixed fat redistribution (P < .0001). Multivariable regression analyses revealed Black women to be most vulnerable to lipodystrophy (P = .02), particularly lipohypertrophy (P < .0001). Conclusions: Ethnicity and gender are important factors influencing lipodystrophy. Combining lipoatrophy and lipohypertrophy into a single entity is not appropriate. Black women were most vulnerable to lipohypertrophy, which has important implications for antiretroviral therapy roll-out in Africa.

AB - Purpose: This study assessed ethnicity and gender differences in prevalence, type, and severity of antiretroviral-associated lipodystrophy in HIV-positive individuals in Ontario. Methods: This was a cross-sectional analysis of the Ontario Cohort Study (OCS), a prospective study of HIV-positive patients in Ontario. Lipodystrophy was defined as at least 1 major or 2 minor self-reported changes of peripheral lipoatrophy and/or central lipohypertrophy. Prevalence, type, and severity were compared by ethnicity (Black, White, or Other) and gender. Univariate and multivariate logistic regression analyses identified predictors of lipodystrophy. Results: Data were available for 778 participants (659 men, 119 women). There were 517 Whites, 121 Blacks, and 140 patients of Other ethnicities. In univariate analyses, Whites reported more peripheral lipoatrophy (P = .004) and abdominal lipohypertrophy (P = .04); these ethnic differences were observed in males (P = .05 and P = .03, respectively) but not females. Males reported more peripheral lipoatrophy (P = .01), whereas females had more central lipohypertrophy (P < .0001) and mixed fat redistribution (P < .0001). Multivariable regression analyses revealed Black women to be most vulnerable to lipodystrophy (P = .02), particularly lipohypertrophy (P < .0001). Conclusions: Ethnicity and gender are important factors influencing lipodystrophy. Combining lipoatrophy and lipohypertrophy into a single entity is not appropriate. Black women were most vulnerable to lipohypertrophy, which has important implications for antiretroviral therapy roll-out in Africa.

KW - HIV

KW - antiretroviral

KW - ethnicity

KW - gender

KW - lipodystrophy

UR - http://www.scopus.com/inward/record.url?scp=79955074091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955074091&partnerID=8YFLogxK

U2 - 10.1310/hct1202-89

DO - 10.1310/hct1202-89

M3 - Article

C2 - 21498152

AN - SCOPUS:79955074091

VL - 12

SP - 89

EP - 103

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 2

ER -